Targeted therapy with low doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.

Background: Palliative treatment ore remains a significant clinical problem.

Objectives: To retrospectively determine the clinical response to 131I-MIBG therapy at low doses in patients with refractory neuroblastoma.

Methods: We performed a retrospective chart review of 10 patients with neuroblastoma treated with 1311-MIBG at Rambam Health Care Campus from 1994 to 2012.